This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Nissan Chemical Industries Limited, Toudai Tlo, Ltd.. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1,235 
1 out of 41 Years Active: 2010
Title: **Shoko Kitajima: Innovator in Adiponectin Research**
Introduction
Shoko Kitajima is a notable inventor based in Tokyo, Japan, who has made significant contributions to the field of obesity and metabolic disease research. With a unique focus on adiponectin expression, Kitajima has developed an innovative approach that may provide therapeutic options for obesity and related health issues.
Latest Patents
Kitajima holds a patent for "Adiponectin expression-inducing agents and uses thereof." This invention encompasses adiponectin expression-inducing agents and therapeutic applications aimed at treating obesity and obesity-related diseases, including cardiovascular and metabolic diseases. The patent details a method for enhancing adiponectin promoter activity through the binding of KLF9, a crucial factor in inducing adiponectin expression. It also proposes KLF9 replenishment therapy as a promising strategy for the prevention and treatment of obesity, insulin resistance, type II diabetes, and cardiovascular conditions.
Career Highlights
Throughout her career, Shoko Kitajima has gained valuable experience working with reputable organizations, notably Nissan Chemical Industries Limited and Toudai Tlo, Ltd. Her expertise in medical research and innovation has led to breakthrough discoveries that highlight the importance of adiponectin in managing obesity and related diseases.
Collaborations
Kitajima has collaborated with esteemed researchers in her field, including Takashi Kadowaki and Toshimasa Yamauchi. These partnerships have helped propel her research forward, showcasing the collaborative nature of scientific advancements in addressing complex health issues.
Conclusion
Shoko Kitajima’s work in the realm of adiponectin expression represents a significant stride towards innovative treatments for obesity and its associated diseases. Her patent reflects a deep understanding of metabolic health and opens avenues for future research and therapeutic interventions. As a dedicated inventor, Kitajima continues to inspire advancements in the medical research community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile